Cannabigerol Combination Therapy for Immunosuppressive Tumor Microenvironments
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments fail to effectively target the immunosuppressive tumor microenvironment (TME) by modulating regulatory myeloid cells, such as MDSCs and M2-like macrophages, which contribute to tumor progression and immune evasion.
Innovation Solution
Administering cannabigerol (CBG) or its pharmaceutical compositions to alter cytokine secretion in the TME, thereby reducing the expansion and activation of regulatory myeloid cells and enhancing the efficacy of immune checkpoint inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitors are administered alone, then they show limited efficacy due to immunosuppressive TME, but combining with CBG increases therapeutic efficacy and complexity of treatment protocol
Solution Approach 1:
The patent combines immune checkpoint inhibitors with CBG (cannabigerol) into a unified treatment protocol for cancer therapy. This merging of two therapeutic agents addresses the limitation of immune checkpoint inhibitors alone by adding CBG's ability to modulate regulatory myeloid cells, thereby enhancing overall therapeutic efficacy while integrating the treatments into a coordinated regimen.
Solution Approach 2:
CBG acts as an intermediary agent that modifies the tumor microenvironment by depleting regulatory myeloid cells and modulating cytokine secretion. This intermediary action creates a more favorable environment for immune checkpoint inhibitors to function effectively, bridging the gap between the immunosuppressive TME and the therapeutic action of checkpoint inhibitors.
2Productivity
If CBG is administered to deplete regulatory myeloid cells, then tumor progression is reduced, but the mechanism of action is complex and not fully understood
Solution Approach 1:
The patent focuses on extracting and targeting the specific function of CBG that depletes regulatory myeloid cells from the complex Cannabis plant metabolite system. By isolating this particular mechanism—CBG's ability to reduce MDSCs and M2-like macrophages through cytokine modulation—the treatment achieves tumor progression control through a defined biological pathway despite the overall complexity of cannabinoid mechanisms.
3Reliability
If single cannabinoids like THC or CBD are used, then some immune modulation occurs, but regulatory myeloid cell depletion is insufficient compared to CBG
Solution Approach 1:
The patent changes the key parameter from using major cannabinoids (THC, CBD) to using the minor cannabinoid CBG, which has demonstrated superior efficacy in depleting regulatory myeloid cells. This parameter change—selecting CBG over more commonly used cannabinoids—achieves enhanced immune modulation and myeloid cell depletion, though it reduces the flexibility of cannabinoid selection based on conventional wisdom.
Data Source
AI summary
The present invention provides a pharmaceutical composition including cannabigcrol. and methods of using same, such as for increasing therapeutic efficacy of an immune checkpoint inhibitor, or for the treatment of cancer.